ImmunoPrecise Announces Participation at the H.C. Wainwright 23nd Annual Global Investment Conference on September 13-15, 2021 (Virtual Conference)

Rhea-AI Summary

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) announced its participation in the H.C. Wainwright 22nd Annual Global Investment Conference, scheduled for September 13-15, 2021. CEO Jennifer Bath will present an overview of the company's activities and engage in one-on-one meetings with institutional investors. The event will be held virtually, and interested investors can register online to attend the presentation on September 10 at 6:00 PM (EDT). ImmunoPrecise aims to revolutionize antibody discovery through innovative technology and comprehensive services.

Positive

• Participation in a prominent investment conference offers visibility to investors.
• CEO engagement in one-on-one meetings highlights the company's commitment to investor relations.

Negative

• None.

VICTORIA, British Columbia--(BUSINESS WIRE)-- IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service, therapeutic antibody discovery and development, today announced that it will be presenting at the H.C. Wainwright Annual Global Investment Conference being held virtually on September 13-15, 2021.

Jennifer Bath, CEO of ImmunoPrecise, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.hcwevents.com) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

Event: H.C. Wainwright 22^nd Annual Global Investment Conference (Virtual Conference)

Date: September 13-15, 2021

Presentation Day & Time: September 10, 6:00 PM (EDT)

Location: https://journey.ct.events/view/8a904567-5abc-4305-b0af-d61d08691320

H.C. Wainwright is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright’s team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.

ImmunoPrecise Antibodies Ltd.

ImmunoPrecise is an innovation-driven technology platform company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of classes of disease targets. The Company aims to transform the conventional multi-vendor antibody discovery model by providing a comprehensive suite of services tailored to optimize antibody genetic diversity and epitope coverage, to discover antibodies against rare and/or challenging epitopes. For further information, visit www.immunoprecise.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005512/en/

Investors:

LifeSci Advisors

John Mullaly

Email: jmullaly@lifesciadvisors.com

Source: ImmunoPrecise Antibodies Ltd.

FAQ

When will ImmunoPrecise Antibodies present at the H.C. Wainwright conference?

ImmunoPrecise Antibodies will present on September 10, 2021, at 6:00 PM (EDT).

What is the date of the H.C. Wainwright 22nd Annual Global Investment Conference?

The conference will take place from September 13-15, 2021.

Who is the CEO of ImmunoPrecise Antibodies?

The CEO of ImmunoPrecise Antibodies is Jennifer Bath.

How can investors attend the ImmunoPrecise presentation?

Investors can register for the conference through the H.C. Wainwright website.

What is the focus of ImmunoPrecise Antibodies' business?

ImmunoPrecise focuses on therapeutic antibody discovery and development.